信迪利单抗联合SOX方案治疗进展期胃癌的疗效

doi:10.3969/j.issn.1671-7171.2026.06.020

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1215 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the clinical efficacy of sintilimab combined with the SOX regimen in the treatment of advanced gastric cancer. 【Methods】 A total of 90 patients with advanced gastric cancer admitted to our hospital between June 2021 and June 2025 were randomly divided into a control group (treated with the SOX regimen) and an observation group (treated with sintilimab combined with the SOX regimen), with 45 patients in each group. Immune function indicators, angiogenesis indicators [endostatin (ES), vascular endothelial growth factor (VEGF), and angiopoietin-2 (Ang-2)], tumor markers [carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA)], functional status [Karnofsky Performance Status (KPS) score], activities of daily living [Activities of Daily Living (ADL) score], and adverse reactions were compared between the two groups before and after treatment. 【Results】 After 4 cycles of treatment, the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in the observation group were significantly higher than those in the control group, while the CD8⁺ level was significantly lower than that in the control group (all P<0.05). The ES level of posttreatment in the observation group was significantly higher than that in the control group, whereas VEGF and Ang-2 levels were significantly lower than those in the control group (P<0.05). Levels of CA125, CA19-9, and CEA in the observation group were significantly lower than those in the control group (P<0.05), while KPS and ADL scores were significantly higher than those in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 Sintilimab combined with the SOX regimen for advanced gastric cancer can effectively enhance immune function, inhibit tumor angiogenesis, reduce tumor marker levels, and improve quality of life, with good safety.

Key words： Stomach Neoplasms Antibodies, Monoclonal Antineoplastic Combined Chemotherapy Protocols Treatment Outcome

Received: 18 July 2025

PACS:

R735.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Zihan
	GAO Zhan
	QIAO Yanjing

Cite this article:

MA Zihan,GAO Zhan,QIAO Yanjing. Efficacy of Sintilimab Combined with the SOX Regimen in the Treatment of Advanced Gastric Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(6): 951-954.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.06.020 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I6/951

[1] 朱麒,肖瑶,金丽艳,等. 曲妥珠单抗联合化疗对HER-2阳性胃癌患者T淋巴细胞亚群及肿瘤标志物的影响[J].临床肿瘤学杂志,2023,28(2):159-163.
[2] 户军燕,邱作栋,周宁,等. 曲妥珠单抗联合SOX方案治疗进展期胃癌的效果及对患者血清肿瘤标志物水平的影响[J].实用癌症杂志,2024,39(1):122-125.
[3] 刘前怡,董洪敏,王文玲,等. 放疗联合化疗和免疫治疗对HER2阴性局部晚期或晚期胃癌的临床疗效和安全性[J].国际肿瘤学杂志,2025,52(4):209-216.
[4] 陆晓,陆屸,金振军,等. 信迪利单抗联合化疗治疗晚期胃癌的疗效及安全性[J].临床药物治疗杂志,2023,21(11):47-51.
[5] 张培培. 信迪利单抗注射液联合化疗在晚期胃癌患者中的应用效果[J].中外医学研究,2025,23(6):29-32.
[6] 中国抗癌协会胃癌专业委员会.胃癌诊治难点中国专家共识(2020版)[J].中国实用外科杂志,2020,40(8):869-904.
[7] 王志超,鲍双振. 调强放疗联合腹腔化疗港治疗对进展期胃癌的效果和作用机制研究[J].中国现代普通外科进展,2025,28(6):479-483.
[8] 尹玉平,孙雄,丁嘉宁,等. 局部进展期胃癌新辅助化疗联合免疫治疗术后复发模式及预后[J].腹部外科,2025,38(2):105-111.
[9] 周丽平,杨朝纲,梅列军,等. 免疫治疗在局部进展期胃癌新辅助治疗中的短期疗效分析[J].实用肿瘤杂志,2025,40(2):152-158.
[10] 陈翠晓,付宝红,曹丽艳,等. 阿帕替尼联合SOX方案治疗晚期胃癌患者的疗效、不良反应及预后的影响因素分析[J].临床和实验医学杂志,2025,24(3):241-245.
[11] 胡发涌,郝天宇,王桂华. 新辅助免疫治疗联合化疗对进展期胃癌及食管胃结合部腺癌围手术期的影响[J].腹部外科,2024,37(4):250-254.
[12] 孙国辉,阿卜杜拉·阿卜迪艾尼,阿尔恒别克·吐尔拜,等. 腹腔热灌注化疗辅助替雷利珠单抗对进展期胃癌患者免疫功能、肿瘤标志物水平的影响[J].疑难病杂志,2024,23(6):641-645.
[13] 张生梅,王亮,毛煜玲,等. 老年进展期胃癌根治术联合SOX化疗方案疗效及安全性[J].中国老年学杂志,2023,43(16):3896-3898.
[14] 李丽,王丹,张宁霞,等. 信迪利单抗联合替吉奥及奥沙利铂对晚期胃癌患者免疫指标及生存情况的影响[J].癌症进展,2025,23(13):1529-1532.
[15] 赵晓敏,丁洁,王娟. 信迪利单抗联合铂类化疗对进展期胃癌患者的免疫指标及生存周期的影响[J].川北医学院学报,2025,40(1):25-28.